{"entity":{"edinet_code":"E00923","sec_code":"4507","name_ja":"塩野義製薬株式会社","name_en":"Shionogi & Co., Ltd.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100Z43Z","filer_name":"塩野義製薬株式会社","filer_name_en":"Shionogi & Co., Ltd.","period_end":"2026-03-31","filed_date":"2026-09-25","sha256":"d500e0d407d744a4f851d5c704bbcbcb8c6cdcb36955885c418f32d67cf19fdc","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"㈱三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":3452430,"book_value_yen":17282000000,"prior_shares":3452430,"prior_book_value_yen":13101000000,"purpose_ja":"同社グループは当社の取引金融機関の一つであるため、財務活動における取引関係維持のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無 (注２)","pct_outstanding":0.09043836038553,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.02550713113757,"pct_of_holder_assets":0.6706585896843845,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東邦ホールディングス㈱","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":3500112,"book_value_yen":16667000000,"prior_shares":3500112,"prior_book_value_yen":15610000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":5.41149198996488,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9890132713036616,"pct_of_holder_assets":0.6467924264708735,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":914000,"book_value_yen":4250000000,"prior_shares":914000,"prior_book_value_yen":3514000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":2.2049554322780143,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2521933403156274,"pct_of_holder_assets":0.16492877017466928,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":1271605,"book_value_yen":3735000000,"prior_shares":1271605,"prior_book_value_yen":2969000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":0.6212083224274639,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.22163344143032196,"pct_of_holder_assets":0.14494328390644465,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ステムリム","held_name_en":"StemRIM Inc.","held_sec_code":"4599","match_status":"matched","shares":4650000,"book_value_yen":1362000000,"prior_shares":4650000,"prior_book_value_yen":1474000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":7.418504142396991,"pct_unavailable":null,"pct_basis_period_end":"2026-07-31","pct_share_classes":1,"pct_of_holder_equity":0.08082054811997283,"pct_of_holder_assets":0.05285481999479989,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱カネカ","held_name_en":"ＫＡＮＥＫＡ ＣＯＲＰＯＲＡＴＩＯＮ","held_sec_code":"4118","match_status":"matched","shares":266600,"book_value_yen":1278000000,"prior_shares":266600,"prior_book_value_yen":1015000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":0.44271447407313924,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0758360209231463,"pct_of_holder_assets":0.04959505136075937,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":344095,"book_value_yen":863000000,"prior_shares":344095,"prior_book_value_yen":551000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":0.07194039293280427,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05121008298644387,"pct_of_holder_assets":0.033490242037821076,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":475000,"book_value_yen":695000000,"prior_shares":475000,"prior_book_value_yen":597000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":0.9798445764344368,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04124102859279083,"pct_of_holder_assets":0.026970704769740034,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":367530,"book_value_yen":338000000,"prior_shares":367530,"prior_book_value_yen":325000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":1.787927729833335,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02005678800627813,"pct_of_holder_assets":0.013116688075067814,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ＭＳ＆ＡＤインシュアランス グループホールディングス㈱","held_name_en":"MS&AD Insurance Group Holdings, Inc.","held_sec_code":"8725","match_status":"matched","shares":65433,"book_value_yen":263000000,"prior_shares":65433,"prior_book_value_yen":211000000,"purpose_ja":"同社グループは当社の取引金融機関の一つであるため、財務活動における取引関係維持のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無 (注２)","pct_outstanding":0.004498904825767076,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.015606317294825882,"pct_of_holder_assets":0.010206180366103063,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ファンペップ","held_name_en":"FunPep Company Limited","held_sec_code":"4881","match_status":"matched","shares":2682500,"book_value_yen":217000000,"prior_shares":2682500,"prior_book_value_yen":308000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":6.613039212302595,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.012876695258468504,"pct_of_holder_assets":0.008421068971271348,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱池田泉州ホールディングス","held_name_en":"Senshu Ikeda Holdings, Inc.","held_sec_code":"8714","match_status":"matched","shares":203725,"book_value_yen":174000000,"prior_shares":203725,"prior_book_value_yen":88000000,"purpose_ja":"同社グループは当社の取引金融機関の一つであるため、財務活動における取引関係維持のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無 (注２)","pct_outstanding":0.07316530119689921,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.010325092050569215,"pct_of_holder_assets":0.006752377884798224,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"オンコセラピー・サイエンス㈱","held_name_en":"OncoTherapy Science, Inc.","held_sec_code":"4564","match_status":"matched","shares":7300000,"book_value_yen":153000000,"prior_shares":7300000,"prior_book_value_yen":204000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":1.9028077100725778,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.009078960251362586,"pct_of_holder_assets":0.0059374357262880935,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アンジェス㈱","held_name_en":"AnGes, Inc.","held_sec_code":"4563","match_status":"matched","shares":1186800,"book_value_yen":67000000,"prior_shares":1186800,"prior_book_value_yen":79000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":0.30506930957247497,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.003975753835564008,"pct_of_holder_assets":0.0026000535533418447,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ロイヤルホテル","held_name_en":"THE ROYAL HOTEL, LIMITED","held_sec_code":"9713","match_status":"matched","shares":654,"book_value_yen":0,"prior_shares":654,"prior_book_value_yen":0,"purpose_ja":"同社は当社の取引先の一つであるため、取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":0.004282047046340195,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":2,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社三井住友フィナンシャルグループ","holder_name_en":"Sumitomo Mitsui Financial Group, Inc.","holder_sec_code":"8316","doc_id":"S100YERK","period_end":"2026-03-31","holder_table":"largest","shares":9651864,"book_value_yen":33482000000,"prior_shares":9651864,"prior_book_value_yen":21678000000,"purpose_ja":"主に預金・融資・為替等の金融関連の取引関係の維持・強化のため保有しております。","reciprocal":"有","pct_outstanding":1.122341747656426,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.21014057238169692,"pct_of_holder_assets":0.010192043865056694,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":15933144000000,"holder_total_assets_yen":328511145000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":3231000,"book_value_yen":11208000000,"prior_shares":3231000,"prior_book_value_yen":7256000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、臨床試験段階にある中枢神経科用薬剤の導入元です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":0.3757083799230814,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.840715914587796,"pct_of_holder_assets":4.0743621994576245,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社カネカ","holder_name_en":"ＫＡＮＥＫＡ ＣＯＲＰＯＲＡＴＩＯＮ","holder_sec_code":"4118","doc_id":"S100YIFD","period_end":"2026-03-31","holder_table":"reporting","shares":2016000,"book_value_yen":6993000000,"prior_shares":2016000,"prior_book_value_yen":4527000000,"purpose_ja":"Health Care Solutions Unitの重要な取引先であり、中長期的な取引関係構築、維持及び強化等を目的に保有しております。","reciprocal":"有","pct_outstanding":0.23442528440883073,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.3405051862387836,"pct_of_holder_assets":0.7290800017515435,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":521669000000,"holder_total_assets_yen":959154000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":1570842,"book_value_yen":5449000000,"prior_shares":1570842,"prior_book_value_yen":3528000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.1826612512953058,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.006554720871999,"pct_of_holder_assets":0.7355750214975816,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東京海上ホールディングス株式会社","holder_name_en":"Tokio Marine Holdings, Inc.","holder_sec_code":"8766","doc_id":"S100YLS8","period_end":"2026-03-31","holder_table":"largest","shares":1486290,"book_value_yen":5155000000,"prior_shares":1486290,"prior_book_value_yen":3338000000,"purpose_ja":"保険事業における顧客企業との長期的かつ安定的な保険取引関係の維持および強化を図り、当社グループの企業価値を高めることを目的として、保有してきたものです。現在は、当社グループのリスクポートフォリオを見直し、社会課題解決や成長分野等に対して資本を振り向けるため、売却方針に則り保有をゼロにすることをめざしています。","reciprocal":"無","pct_outstanding":0.17282934323611163,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0944559401975714,"pct_of_holder_assets":0.016128557903556544,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":5457571000000,"holder_total_assets_yen":31961940000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ＭＳ＆ＡＤインシュアランスグループホールディングス株式会社","holder_name_en":"MS&AD Insurance Group Holdings, Inc.","holder_sec_code":"8725","doc_id":"S100YNCJ","period_end":"2026-03-31","holder_table":"second_largest","shares":1441395,"book_value_yen":5000000000,"prior_shares":1441395,"prior_book_value_yen":3237000000,"purpose_ja":"保険取引先との関係の維持・強化を目的として安定保有していたが、保有方針については③a.(a)に記載のとおり","reciprocal":"有","pct_outstanding":0.16760884564507272,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10362393630029387,"pct_of_holder_assets":0.017457603772797668,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":4825140000000,"holder_total_assets_yen":28640815000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"長瀬産業株式会社","holder_name_en":"NAGASE & CO., LTD.","holder_sec_code":"8012","doc_id":"S100YK28","period_end":"2026-03-31","holder_table":"reporting","shares":1334169,"book_value_yen":4628000000,"prior_shares":1334169,"prior_book_value_yen":2996000000,"purpose_ja":"生活関連セグメントを中心に、医療・医薬・検査薬関連の取引を行っており、同社との良好な関係維持、取引の強化および事業の拡大を図るために保有しております。(注)2","reciprocal":"無","pct_outstanding":0.15514035083057803,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.0662980243073557,"pct_of_holder_assets":0.5310225971456962,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":434025000000,"holder_total_assets_yen":871526000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":1014795,"book_value_yen":3520000000,"prior_shares":1014795,"prior_book_value_yen":2279000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.11800278099784692,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4425451880125572,"pct_of_holder_assets":0.18314236925872085,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ほくやく・竹山ホールディングス","holder_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","holder_sec_code":"3055","doc_id":"S100YJPG","period_end":"2026-03-31","holder_table":"reporting","shares":837000,"book_value_yen":2903000000,"prior_shares":837000,"prior_book_value_yen":1879000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.0973283546875949,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.489429813030636,"pct_of_holder_assets":1.864662620034043,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社岡山製紙","holder_name_en":"Okayama Paper Industries Co.,Ltd.","holder_sec_code":"3892","doc_id":"S100YYF7","period_end":"2026-05-31","holder_table":"reporting","shares":648600,"book_value_yen":1945800000,"prior_shares":648600,"prior_book_value_yen":1561828000,"purpose_ja":"（保有目的）美粧段ボール製品の販売先であり、取引機会と売上拡大を図るために保有しております。（定量的な保有効果）（注１）","reciprocal":"無","pct_outstanding":0.0754207537041506,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":13.43655732447746,"pct_of_holder_assets":10.507156319518854,"holder_equity_basis":"parent_only","holder_equity_yen":14481388000,"holder_total_assets_yen":18518807000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社池田泉州ホールディングス","holder_name_en":"Senshu Ikeda Holdings, Inc.","holder_sec_code":"8714","doc_id":"S100YAWY","period_end":"2026-03-31","holder_table":"largest","shares":376461,"book_value_yen":1305000000,"prior_shares":376461,"prior_book_value_yen":845000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":0.04377578223900438,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5139333028780265,"pct_of_holder_assets":0.01978477500162599,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":253924000000,"holder_total_assets_yen":6595981000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"レイズネクスト株式会社","holder_name_en":"RAIZNEXT Corporation","holder_sec_code":"6379","doc_id":"S100YDME","period_end":"2026-03-31","holder_table":"reporting","shares":123000,"book_value_yen":426000000,"prior_shares":123000,"prior_book_value_yen":276000000,"purpose_ja":"(保有目的)当社のエンジニアリング業における顧客であり、同社との取引関係の維持・強化を図るため、継続して保有しております。","reciprocal":"無","pct_outstanding":0.014302733126134018,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4598991676472811,"pct_of_holder_assets":0.35154315893711835,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":92629000000,"holder_total_assets_yen":121180000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"岡山県貨物運送株式会社","holder_name_en":"Okayamaken Freight Transportation Co., Ltd.","holder_sec_code":"9063","doc_id":"S100YJ0L","period_end":"2026-03-31","holder_table":"reporting","shares":54042,"book_value_yen":187471000,"prior_shares":54042,"prior_book_value_yen":121378000,"purpose_ja":"医薬品輸送に関する貨物自動車運送事業の営業取引維持・強化のため。","reciprocal":"無","pct_outstanding":0.006284132549614103,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6976358988188853,"pct_of_holder_assets":0.36529827886328636,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":26872327000,"holder_total_assets_yen":51319979000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":15636,"book_value_yen":54000000,"prior_shares":15636,"prior_book_value_yen":35000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.0018181913427661098,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006347512186635666,"pct_of_holder_assets":0.004880186893083239,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社マツキヨココカラ＆カンパニー","holder_name_en":"MatsukiyoCocokara&Co.","holder_sec_code":"3088","doc_id":"S100YD1I","period_end":"2026-03-31","holder_table":"reporting","shares":10890,"book_value_yen":37000000,"prior_shares":10890,"prior_book_value_yen":24000000,"purpose_ja":"（保有目的）商品の安定供給（商品仕入）を通じた当社事業の円滑化のため保有（定量的な保有効果）（注）２ ","reciprocal":"無","pct_outstanding":0.0012663151523869874,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006795836539927377,"pct_of_holder_assets":0.004895274208123244,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":544451000000,"holder_total_assets_yen":755831000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":9000,"book_value_yen":20000000,"prior_shares":3000,"prior_book_value_yen":22000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。(注)６","reciprocal":"無","pct_outstanding":0.0010468920453472457,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00715801679986543,"pct_of_holder_assets":0.0058297480382897855,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ＳＯＭＰＯホールディングス株式会社","holder_name_en":"Sompo Holdings, Inc.","holder_sec_code":"8630","doc_id":"S100YC6Z","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":3000573,"prior_book_value_yen":6739000000,"purpose_ja":"上記①イ.保有目的Ａ","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":5167823000000,"holder_total_assets_yen":18603704000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社アインホールディングス","holder_name_en":"AIN HOLDINGS INC.","holder_sec_code":"9627","doc_id":"S100YSTQ","period_end":"2026-04-30","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":60000,"prior_book_value_yen":143000000,"purpose_ja":"業界動向把握のため保有しており、配当金およびその企業に係る収益などをもとに保有効果を見込んでいるため（注）１","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":159171000000,"holder_total_assets_yen":509647000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ＭＳ＆ＡＤインシュアランスグループホールディングス株式会社","holder_name_en":"MS&AD Insurance Group Holdings, Inc.","holder_sec_code":"8725","doc_id":"S100YNCJ","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":1704000,"prior_book_value_yen":3827000000,"purpose_ja":"保険取引先との関係の維持・強化を目的として安定保有していたが、保有方針については②a.(a)に記載のとおり","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":4825140000000,"holder_total_assets_yen":28640815000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社スズケン","holder_name_en":"SUZUKEN CO.,LTD.","holder_sec_code":"9987","doc_id":"S100YFRU","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":3783000,"prior_book_value_yen":8496000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"(注)　１．取引金額等は非開示情報であり、定量的な保有効果の記載が困難なため、保有の合理性を検証した方法を記載しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２．保有先企業は当社の株式を保有しておりませんが、同社子会社が当社の株式を保有しています。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":2,"sale_proceeds_yen":0,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":3,"acquisition_cost_yen":2458000000,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":59715000000,"listed_yen":47353000000,"unlisted_yen":12362000000,"listed_issues":15,"unlisted_issues":45,"equity_yen":1685215000000,"equity_basis":"ifrs_consolidated_excl_nci","total_assets_yen":2576870000000,"assets_basis":"ifrs_consolidated","pct_of_equity":3.54346478045828,"pct_of_assets":2.3173462378777354,"equity_basis_label":"Consolidated equity attributable to owners of the parent (IFRS)","assets_basis_label":"Consolidated total equity (IFRS)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":47353000000,"issue_count":15,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":12362000000,"issue_count":45,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2021","period_end":"2021-03-31","policy_total_yen":50648000000,"equity_yen":846108000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":5.98599705947704,"pct_of_assets":5.069910469753512},{"year":"2022","period_end":"2022-03-31","policy_total_yen":47203000000,"equity_yen":975661000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":4.83805338124615,"pct_of_assets":4.102464711920118},{"year":"2023","period_end":"2023-03-31","policy_total_yen":43668000000,"equity_yen":1100046000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.9696521781816396,"pct_of_assets":3.3288611068760483},{"year":"2024","period_end":"2024-03-31","policy_total_yen":44070000000,"equity_yen":1235325000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.567482241515391,"pct_of_assets":3.1102717306153216},{"year":"2025","period_end":"2025-03-31","policy_total_yen":49282000000,"equity_yen":1361924000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.618557276323789,"pct_of_assets":3.2098239553352363},{"year":"2026","period_end":"2026-03-31","policy_total_yen":59715000000,"equity_yen":1685215000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.54346478045828,"pct_of_assets":2.3173462378777354}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2019","period_end":"2019-03-31","named_holdings":27,"book_value_yen":59619000000},{"year":"2021","period_end":"2021-03-31","named_holdings":20,"book_value_yen":43052000000},{"year":"2022","period_end":"2022-03-31","named_holdings":19,"book_value_yen":38138000000},{"year":"2023","period_end":"2023-03-31","named_holdings":20,"book_value_yen":36843000000},{"year":"2024","period_end":"2024-03-31","named_holdings":21,"book_value_yen":35677000000},{"year":"2025","period_end":"2025-03-31","named_holdings":16,"book_value_yen":40046000000},{"year":"2026","period_end":"2026-03-31","named_holdings":15,"book_value_yen":47344000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}